Published in JAMA Network Open, a new study found that less than half of Medicaid plans cover all four of the FDA-approved medications, which include acamprosate, disulfiram, and oral and injectable naltrexone. While 90 percent of Medicaid MCPs cover at least one of the AUD medications, only 43 percent cover all four options. The majority of these plans covered naltrexone—84 percent covered the oral version and 73 percent covered the injectable version—while 63 percent of MCPs covered disulfiram and 55 percent covered acamprosate.

Outpatient primary care clinics at Hebrew SeniorLife’s Orchard Cove and NewBridge on the Charles communities have been recognized by the Institute for Healthcare Improvement (IHI) as Age-Friendly Health Systems — Committed to Care Excellence.

Thomas Jefferson University has initiated a phase 1 clinical trial for a Lassa virus (LASV) vaccine developed at Jefferson in collaboration with the University of Maryland, Baltimore (UMB), at the Center of Vaccine Development and Global Health, UMB. Currently, there are no approved vaccines against the Lassa virus. The clinical study is a dose-ranging study that will assess the safety and immunogenicity of the candidate vaccine for both the rabies virus and LASV.

Researchers at Washington University in St. Louis use machine learning to improve compliance of HIV treatments.

The American College of Cardiology (ACC) has issued its first Concise Clinical Guidance (CCG) to create more streamlined and efficient processes to implement best practices in patient care. This CCG focuses on evaluating and managing cardiogenic shock (CS), addressing important questions around clinical decision-making and providing actionable guidance for health care providers.

By unraveling the complex choreography of cellular machinery, Michigan State University researchers are helping identify the next generation of drug targets and cancer therapies.

Led by Jian Hu and Kennie Merz, the MSU team has unveiled new insights into a family of proteins that, while vital for cellular functions, are also linked to an array of diseases such as breast, ovarian and pancreatic cancers.

Understanding these dynamic proteins found in cell membranes — called Zrt-/Irt-like proteins, or ZIPs for short — will contribute to the search for cutting-edge drug therapies and the improved health of patients.